Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) shares rose 10.2% during mid-day trading on Monday . The company traded as high as $10.12 and last traded at $10.18. Approximately 233,318 shares traded hands during mid-day trading, a decline of 29% from the average daily volume of 330,797 shares. The stock had previously closed at $9.23.
Upstream Bio Price Performance
The stock's 50-day moving average is $8.41 and its 200-day moving average is $11.56.
Upstream Bio (NASDAQ:UPB - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.02). The company had revenue of $0.57 million for the quarter, compared to analysts' expectations of $0.71 million. On average, equities analysts forecast that Upstream Bio, Inc. will post -4.3 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of UPB. BNP Paribas Financial Markets bought a new position in Upstream Bio during the fourth quarter valued at about $25,000. US Bancorp DE bought a new position in Upstream Bio during the fourth quarter valued at about $27,000. Legal & General Group Plc bought a new position in Upstream Bio during the fourth quarter valued at about $28,000. New York State Common Retirement Fund bought a new position in Upstream Bio during the first quarter valued at about $29,000. Finally, Summit Investment Advisors Inc. bought a new position in Upstream Bio during the fourth quarter valued at about $30,000.
About Upstream Bio
(
Get Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Further Reading
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
